Financials Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 19:46:20 12/07/2024 BST 5-day change 1st Jan Change
54.52 USD +12.40% Intraday chart for Legend Biotech Corporation +15.57% -11.07%

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,735 7,175 8,357 10,938 8,841 - -
Enterprise Value (EV) 1 3,233 6,446 7,855 9,959 7,985 8,114 7,828
P/E ratio -22 x -34 x -35.7 x -40.9 x -46.5 x -87.1 x 157 x
Yield - - - - - - -
Capitalization / Revenue 49.4 x 79.9 x 71.4 x 38.4 x 16.2 x 8.61 x 5.66 x
EV / Revenue 42.7 x 71.8 x 67.1 x 34.9 x 14.7 x 7.9 x 5.01 x
EV / EBITDA -14.6 x -17.9 x -17.7 x -25.4 x -22.1 x -80.8 x 34.7 x
EV / FCF -12 x -26.6 x -33.1 x -24.1 x -19.6 x -52.8 x 50.2 x
FCF Yield -8.31% -3.76% -3.02% -4.15% -5.11% -1.9% 1.99%
Price to Book 26.7 x 30.5 x - 17.5 x 9.35 x 9.9 x 6.75 x
Nbr of stocks (in thousands) 132,638 153,946 167,403 181,789 182,283 - -
Reference price 2 28.16 46.61 49.92 60.17 48.50 48.50 48.50
Announcement Date 18/03/21 18/03/22 30/03/23 11/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 75.68 89.79 117 285.1 544.8 1,027 1,561
EBITDA 1 -220.8 -360.6 -443.2 -392.1 -361.2 -100.4 225.6
EBIT 1 -229.2 -373 -455.8 -412.6 -381.9 -162 172.4
Operating Margin -302.87% -415.44% -389.58% -144.69% -70.09% -15.78% 11.04%
Earnings before Tax (EBT) 1 -307.6 -386.2 -445.7 -520.1 -324.1 -159.5 171.2
Net income 1 -303.5 -386.2 -446.3 -518.3 -322.5 -153.5 153.7
Net margin -401.02% -430.12% -381.48% -181.75% -59.19% -14.94% 9.84%
EPS 2 -1.280 -1.370 -1.400 -1.470 -1.044 -0.5567 0.3093
Free Cash Flow 1 -268.8 -242.4 -237 -413.4 -407.8 -153.8 155.8
FCF margin -355.14% -269.92% -202.57% -144.97% -74.85% -14.98% 9.98%
FCF Conversion (EBITDA) - - - - - - 69.04%
FCF Conversion (Net income) - - - - - - 101.38%
Dividend per Share 2 - - - - - - -
Announcement Date 18/03/21 18/03/22 30/03/23 11/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 39 40.83 11.97 36.34 73.33 96.01 79.46 93.99 123.4 142.3 189.2 188.8 241.8
EBITDA 1 -114.2 - -116.1 - - -53.64 - -48.59 -106 -109.1 -100.5 -56.7 -56.73
EBIT 1 -117.5 -76 -125.5 -106.9 -104.3 -56.82 -141 -54.31 -91.38 -102.2 -90.12 -76.03 -36.47
Operating Margin -301.22% -186.16% -1,048.6% -294.09% -142.25% -59.18% -177.43% -57.79% -74.08% -71.81% -47.62% -40.27% -15.08%
Earnings before Tax (EBT) 1 -88.33 -41.09 -193.1 -112 -198.8 -62.5 -146.8 -59.79 -90.91 -92.8 -76.89 -74.49 -35.17
Net income 1 -88.33 -41.09 -193.2 -112.1 -199.1 -62.21 -144.8 -59.79 -90.86 -92.62 -76.47 -74.56 -35.26
Net margin -226.53% -100.64% -1,614.13% -308.51% -271.55% -64.79% -182.24% -63.62% -73.66% -65.06% -40.41% -39.49% -14.58%
EPS 2 -0.3000 -0.1300 -0.6200 -0.3400 -0.5700 -0.1700 -0.4000 -0.1600 -0.2624 -0.3011 -0.2745 -0.2060 -0.1120
Dividend per Share 2 - - - - - - - - - - - - -
Announcement Date 18/03/22 01/06/22 17/02/23 18/05/23 15/08/23 20/11/23 11/03/24 13/05/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 502 729 501 979 855 727 1,013
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 -269 -242 -237 -413 -408 -154 156
ROE (net income / shareholders' equity) -284% -103% -59.1% -51.9% -32% -15.1% 18.4%
ROA (Net income/ Total Assets) -44.3% -42% -36.4% -32.6% -24% -14.5% 11.4%
Assets 1 684.9 919.7 1,225 1,590 1,341 1,061 1,353
Book Value Per Share 2 1.050 1.530 - 3.440 5.190 4.900 7.180
Cash Flow per Share 2 - - - - -0.9000 -0.8100 0.1800
Capex 1 45.7 43.9 35.7 20.1 34.3 34.1 35.7
Capex / Sales 60.45% 48.9% 30.54% 7.04% 6.3% 3.32% 2.28%
Announcement Date 18/03/21 18/03/22 30/03/23 11/03/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
48.5 USD
Average target price
82.5 USD
Spread / Average Target
+70.11%
Consensus
  1. Stock Market
  2. Equities
  3. LEGN Stock
  4. Financials Legend Biotech Corporation